Bently Patrick Doonan

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib

Christina A. Von Roemeling, Bently Patrick Doonan, Savannah L. Carpenter, Jeet A. Patel et autres

Current advances in the treatment of melanoma brain metastases through immune checkpoint blockade and targeted therapy has significantly improved outcomes and patient survival. Yet, half of all patients continue to die from brain metastases despite use of these therapies and the addition …

us (code pays fourni par la source)

Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Overview plot showing longitudinal ctDNA status, treatment regimen, and clinical outcomes for patients with stages I–IIIb melanoma who had radiographic recurrence after surgery. Arrows represent time from the first ctDNA-positive result to recurrence. NED, no evidence of disease; T-VEC, talimogene laherparepvec.

Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Study cohort demographics.

Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Flow diagram depicting the number of patients included in our study. Patient number is further stratified by stage, receipt of systemic adjuvant treatment or not, and ctDNA outcomes, followed by the number of patients who relapsed or not.

Supplementary Figure 8 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Recurrence-free survival stratified by ctDNA status within Stage II and Stage III melanoma. (A) Kaplan–Meier recurrence-free survival (RFS) curves for patients with Stage II melanoma, stratified by longitudinal ctDNA status. Patients who were ctDNA-positive at any postoperative timepoint experienced significantly inferior RFS …

Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging …

Supplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Overview plot of patients with stage IIC melanoma.

Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Representativeness of the study participants

Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed …

Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Association between ctDNA and RFS. A, Kaplan–Meier estimates for RFS stratified by longitudinal ctDNA status. Patients who experienced anytime ctDNA positivity demonstrated shorter RFS compared with patients with serially negative ctDNA. B, Kaplan–Meier estimates for distant/regional RFS stratified by longitudinal ctDNA status. …

Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Overview plot of patients with stage IIB melanoma.

Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin et autres

Overview plot of patients with stage IA/B melanoma.